TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00619931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: APD791 or matching placebo in escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: APD791 or matching placebo in escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: APD791 or matching placebo in escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: APD791 or matching placebo in escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: APD791 or matching placebo in escalating doses
Study: NCT00474838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensive insulin group
Description: Once daily long acting insulin and preprandial rapid acting insulin injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral AntiDiabetic Drug (glimepiride and metformin)
Description: glimepiride and metformin combined therapy
Study: NCT02778971

Intervention type: DRUG
Intervention: [18F]Flutemetamol
Description: amyloid PET imaging with \[18F\]Flutemetamol and subsequent modification of diagnosis and management
Study: NCT00695578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biafine
Description: Apply to wounds 3 times daily for 4 weeks: ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biafine
Description: Apply to wounds 3 times daily for 4 weeks: ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polysporin
Description: over the counter Polysporin ointment 3 times daily for 4 weeks to wounds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polysporin
Description: over the counter Polysporin ointment 3 times daily for 4 weeks to wounds
Study: NCT00006363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valspodar
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous PBSCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical observation
Description: Undergo clinical observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02518620

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Description: Subjects received ALX-0061 150 mg s.c. injections, beginning at Week 0 and q2w thereafter, up to and including Week 102. Subjects from the preceding study ALX0061-C201 also continued their MTX treatment.
Study: NCT00467909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: micronutrients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: micronutrients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: micronutrients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: micronutrients
Study: NCT04389476

Intervention type: OTHER
Intervention: Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19)
Description: Establish standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) for the different tiers of medical staff, patients, and community residents.~Then explore the psychological impact and mental disabilities under the intervention and controlling related factors.
Study: NCT00006363

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00542568

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EPODURE (dermal Biopump for erythropoietin)
Description: Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EPODURE (dermal Biopump for erythropoietin)
Description: Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EPODURE (dermal Biopump for erythropoietin)
Description: Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
Study: NCT01442038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.
Study: NCT02275936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: S Nitrosoglutathione Reductase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: S Nitrosoglutathione Reductase Inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N91115
Description: S Nitrosoglutathione Reductase Inhibitor
Study: NCT02743312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Weights
Description: Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss. The garment is then taken by another investigator and the actual weights are replaced with sham weights.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Weights
Description: Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss. The garment is then taken by another investigator and the actual weights are replaced with sham weights.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Flex
Description: Potential effect on participants' physical activity to see their own step count using this wrist-worn remote monitoring device.
Study: NCT01442038

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.
Study: NCT00089284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin gadolinium
Description: Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111Indium-Zevalin and 90Yttrium-Zevalin
Description: Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
Study: NCT02237911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinic-based outpatient exercise group
Description: Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based exercise group
Description: Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
Study: NCT04535765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early warm water sitz bath
Description: The experimental group started the warm water sitz bath 6 hours after the end of the hemorrhoid surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Regular time warm water sitz bath
Description: According to the routine, the control group started the warm water sitz bath on the first day after the hemorrhoid surgery.
Study: NCT02743312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Flex
Description: Potential effect on participants' physical activity to see their own step count using this wrist-worn remote monitoring device.
Study: NCT01730729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabergoline
Description: Given orally
Study: NCT02584738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Magnesium Sulfate
Description: Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized isotonic saline
Description: Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Salbutamol
Description: Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized Salbutamol
Description: Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)
Study: NCT02584699

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Description: Six Gy irradiation per fraction times 12 fractionations, resulting a total dose of 72Gy
Study: NCT04280146

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: daily energy intake
Description: Investigate daily energy intake according to eating rate and food processing
Study: NCT02584738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Description: Nebulized ipratropium bromide 250 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ipratropium bromide
Description: Nebulized ipratropium bromide 250 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone or Prednisolone
Description: Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone or Prednisolone
Description: Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
Study: NCT02895984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-session alcohol intervention (BMI)
Description: The intervention recipients will receive a 1-hour individual BMI. The BMI will follow the central principles of Motivational Interviewing (MI) and will include all the components determined to be efficacious in existing multi-component BMIs (e.g., personalized feedback on indicators of alcohol-related risk, including signs of alcohol dependence and family history of alcohol risk; normative comparisons of the participant's alcohol consumption with same-sex peers in his/her dorm and throughout campus, and protective behavioral strategies). Additional components will include reviewing the pros and cons of the participant's current pattern of alcohol use, providing estimates of the participant's recent Blood Alcohol Concentration (BAC), and providing information about risks of specific negative outcomes at different levels of drinking. Participants will identify goals for behavior change, and with the counselor will develop a plan to achieve the goals and to address barriers to success.
Study: NCT02157727

Intervention type: DEVICE
Intervention: Infants hospitalized in health facilities performing Tele-expertise
Study: NCT02510742

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostimulation
Description: Neurostimulation of sphenopalatine ganglion (SPG) of 20 Hz

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation of sphenopalatine ganglion (SPG) with amplitude=0
Study: NCT02783677

Intervention type: PROCEDURE
Intervention: Percutaneous balloon angioplasty
Study: NCT02147028

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hippocampal sparing whole brain radiotherapy
Description: 30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional whole brain radiotherapy
Description: 30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
Study: NCT02239224

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Concentrate for solution for infusion
Study: NCT00594997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Students receive an educational intervention delivered by a member of our staff in conjunction with the teacher as well as a health education entertainer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (pre and post surveys)
Description: Students fill out a pre and post survey and then receive the same intervention given to the controls.
Study: NCT02796482

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: EnergieShake 1.5kcal Complete
Description: Participants will be given EnergieShake 1.5 kcal Complete drink twice daily. i.e. 2 bottles of ONS per day during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days, followed by 8 day intervention on EnergieShake 1.5 kcal Complete drink.
Study: NCT01118637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StopPulling.com
Description: subsidized access to an interactive self-help website for TTM
Study: NCT01668199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Study: NCT05067985

Intervention type: PROCEDURE
Intervention: covid 19 spinal anesthesia
Description: this group description covers that all the covid 19 pregnant women which we gave spinal anesthesia for cesarean section procedures. The investigators analyzed them retrospectively.
Study: NCT02633891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance exercise
Description: tailored balance exercise program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: general health education and fall prevention classes
Study: NCT02862704

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG7-CART
Description: Ultrasound-guided intra-tumor injection as the route of T cell delivery, so that more T cells gathered at the tumor site, less migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And MG7-CART is a 2nd CAR, with MG7 as the target protein, 4-1BB as co- stimulator
Study: NCT03558113

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: light induced fluorescence intraoral camera
Description: intraoral oral light induced fluorescence diagnostic camera
Study: NCT03631147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 400mg bid for 8 weeks
Study: NCT02239224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATYR1940
Description: Concentrate for solution for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATYR1940
Description: Concentrate for solution for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATYR1940
Description: Concentrate for solution for infusion
Study: NCT00478881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil HCl (Levitra, BAY38-9456)
Description: vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
Study: NCT03031236

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice
Description: The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
Study: NCT01466179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous infusion over four weeks per treatment cycle
Study: NCT01640626

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education package
Description: Health Education package that covers key health messages about the proper personal hygiene practices will be given to school children in the intervention school. The package consisted of many items such as posters, comic book, song video, competitions, drawing activities, puppet show, etc.
Study: NCT02921360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Study: NCT02725853

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Application of 1.5 mA tDCS for 30 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Application of 1.5 mA tDCS for 30 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Application of sham tDCS for 30 minutes

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: personalized practice
Description: arm exercise consisting of whole arm movement within a restricted elbow range of motion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized practice
Description: arm exercise consisting of whole arm movement within a restricted elbow range of motion
Study: NCT02862262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARIES Bordetella Assay

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARIES Bordetella Assay

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARIES Bordetella Assay
Study: NCT03829514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: 40 patients (20 males and 20 females) aged 18-70 years, with type 2 diabetes and triglycerides \>150 mg/dL will be recruited. They will have a physical exam and blood draw at visit 1. Participants will receive 160 mg fenofibrate to be taken orally daily for six weeks. They will return for a second visit after 6 weeks and have blood draw as follow up.
Study: NCT04174482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: morphological and functional evaluation of adult flat foot
Description: Evaluations are realized by weight bearing computed tomography and by Gait analysis in the pre-operative phase and at a 6-months follow-up from the surgery with Grice technique